## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Corporate Governance recommendations and practices</td>
<td>3</td>
</tr>
<tr>
<td>Management and Board committees</td>
<td>3</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>3</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence, attendance and diversity</td>
<td>4</td>
</tr>
<tr>
<td>Chairmanship</td>
<td>5</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence and attendance</td>
<td>5</td>
</tr>
<tr>
<td>Chairmanship Report for 2019</td>
<td>5</td>
</tr>
<tr>
<td>The Nomination Committee</td>
<td>5</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence and attendance</td>
<td>5</td>
</tr>
<tr>
<td>Nomination Committee Report for 2019</td>
<td>6</td>
</tr>
<tr>
<td>Audit Committee</td>
<td>6</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence and attendance</td>
<td>6</td>
</tr>
<tr>
<td>Audit Committee Report for 2019</td>
<td>6</td>
</tr>
<tr>
<td>Remuneration Committee</td>
<td>7</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence and attendance</td>
<td>7</td>
</tr>
<tr>
<td>Remuneration Committee Report for 2019</td>
<td>8</td>
</tr>
<tr>
<td>Research &amp; Development Committee</td>
<td>8</td>
</tr>
<tr>
<td>Roles and responsibilities, composition, independence and attendance</td>
<td>8</td>
</tr>
<tr>
<td>Research &amp; Development Committee Report for 2019</td>
<td>9</td>
</tr>
<tr>
<td>Risk management</td>
<td>9</td>
</tr>
<tr>
<td>The enterprise risk management system</td>
<td>9</td>
</tr>
<tr>
<td>Internal control</td>
<td>10</td>
</tr>
<tr>
<td>Overall control environment</td>
<td>10</td>
</tr>
<tr>
<td>Risk assessment</td>
<td>10</td>
</tr>
<tr>
<td>Control activities</td>
<td>10</td>
</tr>
<tr>
<td>IT systems</td>
<td>11</td>
</tr>
<tr>
<td>Monitoring</td>
<td>11</td>
</tr>
<tr>
<td>Appendix 1</td>
<td>12</td>
</tr>
<tr>
<td>Deviations from Nasdaq Copenhagen</td>
<td>12</td>
</tr>
<tr>
<td>Corporate Governance Recommendations</td>
<td>12</td>
</tr>
<tr>
<td>Appendix 2</td>
<td>14</td>
</tr>
<tr>
<td>Summary of the significant ways in which Novo Nordisk’s corporate governance practices differ from the NYSE Corporate Governance Listing Standards</td>
<td>14</td>
</tr>
</tbody>
</table>
Statutory Corporate Governance Report for 2019

Introduction


The sections Management and Board Committees, Risk Management and Internal Control are a part of the auditor’s certificate in the statutory Annual Report, whereas the sections Corporate Governance Recommendations and Practices and Appendix 1 and Appendix 2 are not a part of the auditor’s certificate in the statutory Annual Report.

Corporate Governance recommendations and practices

As an international company listed on the stock exchanges in Copenhagen and New York, Novo Nordisk is subject to the Danish Corporate Governance Recommendations designated by Nasdaq Copenhagen, and – as a foreign listed private issuer – to the Corporate Governance Listing Standards on New York Stock Exchange as stated in the NYSE Listed Company Manual.

The Danish Corporate Governance Recommendations

The Danish Corporate Governance Recommendations were updated in November 2017. Novo Nordisk is in compliance with all but the following five recommendations where Novo Nordisk instead explains its approach:

3.3.2 - Disclosure of additional information about Board members: Information on matters such as number of shares owned and changes during the year is disclosed in the Remuneration Report for 2019 and not in the management commentary.

3.4.2 - Independence of Board committees: the majority of the members of the Nomination Committee and the Remuneration Committee are not independent.

3.4.6 - Tasks of the Nomination Committee: responsibility for succession management and recommending candidates for the executive management resides with the Chairmanship and not with the Nomination Committee.

3.4.7 - Tasks of the Remuneration Committee: responsibility for the remuneration policy applicable to employees in general resides with Executive Management and not with the Remuneration Committee.

4.1.5 - Termination payments: one executive’s employment contracts entered into before 2008 allow for severance payments of more than 24 months’ fixed base salary plus pension contribution and thus the total value of the remuneration relating to the notice period and of the severance payment exceeds two years of remuneration.

For a review of Novo Nordisk’s explanations to the five recommendations above, please see Appendix 1.

For a review of Novo Nordisk’s compliance with and explanations to all applicable Danish Corporate Governance recommendations, please refer to Novo Nordisk’s webpage.

Corporate Governance Standards of the New York Stock Exchange

As a foreign listed private issuer Novo Nordisk is in compliance with the corporate governance standards of the New York Stock Exchange, where Novo Nordisk’s ADRs are listed.

For a summary of the significant ways in which Novo Nordisk’s corporate governance practices differ from the NYSE Corporate Governance Listing Standards, please see Appendix 2.

For a review of Novo Nordisk’s compliance with and explanations to all the applicable NYSE Corporate Governance recommendations, please refer to Novo Nordisk’s webpage.

Management and Board committees

The company has a two-tier management structure consisting of the Board of Directors and Executive Management. The Board of
Directors supervises the performance of the company and ensures adequate management and organisation. It also participates in determining the company strategy. Executive Management, in turn, has responsibility for the company’s daily operations. The two bodies are separate, and no one serves as a member of both.

### Board of Directors

**Roles and responsibilities, composition, independence, attendance and diversity**

The Board of Directors has 13 members, nine of whom are elected by shareholders at general meetings and four of whom are elected by the employees based in Denmark. The guiding principle in composing the Board of Directors is that it should comprise individuals whose particular knowledge and experience enables the Board of Directors as a whole to attend to the interests of shareholders, employees and other stakeholders.

The Board of Directors determines the company’s overall strategy and follows up on its implementation, supervises the performance, ensures adequate management and organisation and, as such, actively contributes to developing the company as a focused, sustainable, global pharmaceutical company. The Board of Directors supervises Executive Management. The Board of Directors may also distribute extraordinary dividends, issue new shares or repurchase shares in accordance with authorisations granted by the annual general meeting and recorded in the meeting minutes. For the minutes of annual general meetings, see novonordisk.com/about_us.

In March 2019 the shareholders elected the following members to the Board of Directors:

- Helge Lund (chair of the Board of Directors since 2018 (member since 2017? and chair of the Nomination Committee)
- Jeppe Christiansen (vice chair and member of the Board of Directors since 2013 and chair of the Remuneration Committee)
- Brian Daniels (member of the Board of Directors since 2016 and member of the Remuneration Committee and the Research & Development Committee)
- Laurence Debroux (Member of the Board of Directors since 2019 and member of the Audit Committee)
- Andres Fibig (member of the Board of Directors since 2018 and member of the Audit Committee)
- Sylvie Grégoire (member of the Board of Directors since 2015, member of the Audit Committee, the Nomination Committee and the Research & Development Committee)
- Liz Hewitt (member of the Board of Directors since 2012, chair of the Audit Committee and member of the Remuneration Committee)
- Kasim Kutay (member of the Board of Directors since 2017 and member of the Nomination Committee)
- Martin Mackay (member of the Board of Directors since 2018 and chair of the Research & Development Committee)

The shareholder elected board members are elected or re-elected annually at the annual general meeting.

In 2018 the employees elected the following members to the Board of Directors (elected for a statutory four-year term):

- Mette Bøjer Jensen (member of the Board of Directors since 2018 and member of the Nomination Committee – employee representative)
- Anne Marie Kverneland (member of the Board of Directors since 2000 and member of the Remuneration Committee – employee representative)
- Thomas Rantzau (member of the Board of Directors since 2018 and member of the Research & Development Committee – employee representative)
- Stig Strøbaek (Member of the Board of Directors since 1998 and member of the Audit Committee – employee representative)

The employee-elected board members are up for election in 2022.

Seven of the nine shareholder-elected board members are independent as defined by the Danish Corporate Governance Recommendations, while two shareholder-elected board members are related to the main shareholder Novo Holdings A/S as member of either the board or executive management and thus are not deemed independent. Employee representatives are considered non-independent according to the Danish Corporate Governance Recommendations.

In 2019, the Board of Directors conducted eight board meetings. All board members attended all board meetings within the member’s term in 2019, except one member who was excused from one meeting within the member’s term in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview, which also includes the attendance for committee meetings.

To ensure that discussions include multiple perspectives representing the complex, global pharmaceutical environment, the Board of Directors aspires to be diverse in gender and nationality. In 2016, the Board of Directors adjusted its diversity ambition and set out new targets with the aim of consisting, by 2020, of at least two shareholder-elected board members with Nordic nationality and at least two shareholder-elected board members with a nationality other than Nordic – and at least three shareholder-elected board members of each gender.

As of 31 December 2019, three shareholder-elected board members were female and six were male, while seven of the nine shareholder-elected board members were non-Nordic and two were Nordic. The company thus fulfilled its nationality ambition and its gender ambition. The Board of Directors will revisit its diversity ambition in 2020 and, if needed, adjust the numbers and parameters which are currently fulfilled.
Chairmanship

Roles and responsibilities, composition, independence and attendance
The annual general meeting elects the chair and vice chair of the Board of Directors directly.

The Chairmanship carries out administrative tasks, such as planning board meetings to ensure a balance between overall strategic setting and financial and managerial supervision of the company. Other tasks include reviewing the fixed asset investment portfolio. At the annual general meeting in March 2019, Helge Lund was re-elected as a chair of the Board of Directors and Jeppe Christiansen was re-elected as vice chair. Helge Lund became chair of the Board in 2018 and Jeppe Christiansen became vice chair in connection with his first election in 2013.

The chair is considered independent, but the vice chair is non-independent, as he is a board member of the main shareholder, Novo Holdings A/S.

In 2019, the Chairmanship conducted eight meetings. The chair attended all meetings in 2019 and the vice chair was excused from two meetings in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview.

Chairmanship Report for 2019
The Chairmanship works according to an Annual Work Plan with fixed agenda items. In addition, the Chairmanship requests ad hoc topics to be discussed at their meetings.

In 2019, the Chairmanship met eight times and dealt with the following matters:

Board matters and governance
- Prepared the Board’s Annual Wheel for 2020.
- Prepared each Board meeting including preparation of the agenda and review of key recommendations to the Board regarding business performance and proposals for budgets/targets, business plans, strategies/policies, investments, financial reporting, shareholders meetings and ensured follow up on decisions made by the Board.
- Reviewed and suggested changes to the documents governing the Board and committees, incl. the Rules of Procedure of the Board, the Chairmanship Charter, charters for the Board committees and the Guidelines for Executive Management.
- Conducted the annual review of the company’s takeover response capabilities.
- Conducted a review of the company’s investment portfolio.

Annual General Meeting and shareholders
- Reviewed the recommended agenda for the 2019 Annual General Meeting.
- Conducted meetings with 8 of Novo Nordisk’s large shareholders.

Executive Management and organisation
- Reviewed the organisational structure and employee composition as well as the future need for competences.
- Reviewed the composition of and the succession plan for the Executive Management, including the appointments to the Executive Management.
- Reviewed the achievement of the LTIP 2018 targets and recommended to the Board the targets for LTIP 2019.
- Conducted the annual performance evaluation of the Executive Management.

Special focus areas
- Commercialisation – commercial execution within the therapy areas and in different markets.
- External innovation – partnering and acquisition to access external innovation.
- Organisational development – talent and leadership development, supervising the changes in Executive Management and development of the company culture.

The Nomination Committee

Roles and responsibilities, composition, independence and attendance
The Nomination Committee has four members elected by the Board of Directors from among its members. One member is designated as chair and one member is an employee representative. The Nomination Committee assists the Board of Directors with oversight of a) the competence profile and composition of the Board of Directors, b) nomination of members of the Board of Directors, c) nomination of members of the Board committees, d) the corporate governance of the company, and e) other tasks on an ad hoc basis as specifically decided by the Board of Directors. The Board of Directors has in March 2019 elected the following members to the Nomination Committee:

- Helge Lund (re-elected, member since 2017 and chair since 2018; independent)
- Sylvie Gregoire (re-elected, member since 2018; independent)
- Kasim Kutay (re-elected, member since 2017; not independent)
- Mette Bøjer Jensen (re-elected, member since 2018; employee representative, not independent)

The Nomination Committee consists of two members who are independent, as defined in the Danish Corporate Governance Recommendations, including the chair, and two members who are non-independent. One member is an employee representative. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Nomination Committee does not conform to the Danish Corporate Governance Recommendations. This is due to the fact that the Board of Directors finds that the composition of the Nomination Committee allows for a representative of the main shareholder, who qualifies as a non-independent Board member, as well as an employee representative, who also qualifies as a non-independent Board member, being on the Nomination Committee while maintaining an
operational structure of the Nomination Committee with relative few members.

The Nomination Committee conducted three meetings in 2019. All Nomination Committee members attended all committee meet-
ing within the member’s term in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview.

Nomination Committee Report for 2019
The Nomination Committee works according to an Annual Work Plan with fixed agenda items. In addition, the Nomination Committee conducts a search process for potential candidates for the Board.

In 2019 the Nomination Committee met three times and dealt with the following matters:

Board composition
• Discussed the desired competences to be represented on the Board.
• Reviewed the Board members’ competences based on the desired competences.
• Reviewed the composition of the Board in relation to diversity.
• Reviewed the composition of the Board and discussed long term succession planning.

Search for and nomination of Board members
• Established search profile, conducted search, including interviews of potential candidates and recommended to the Board specific proposals for the nomination of individual members to be elected at the Annual General Meeting as chair, vice chair and board members.
• Reviewed the composition of the Board committees and recommended to the Board specific proposals for the election of individual members as Board committee members.

Nomination Committee matters and governance
• Endorsed the Annual Work Plan for 2019.
• Conducted a self-evaluation including a review of the Nomination Committee charter.
• Conducted private meetings without the assigned executive being present.
• Endorsed a report on the Nomination Committee’s activities.

Special focus areas
• Nomination of Board candidates – reviewing the composition of the Board and consider the long-term succession planning
• Competences – reviewed the desired competences to be represented on the Board.

Audit Committee

The Audit Committee assists the Board with the oversight of: a) the external auditors, b) the internal audit function, c) the procedure for handling complaints reported through the Compliance Hotline (whistleblowing), d) financial, social and environmental reporting, e) business ethics compliance, f) information security, g) insurance coverage, and h) special theme reviews and other tasks on an ad hoc basis, as specifically decided by the Board.

The Board of Directors has in March 2019 elected the following members to the Audit Committee:

- Liz Hewitt (re-elected, member since 2012 and chair since 2015; independent; financial expert)
- Laurence Debroux (elected, member since 2019, independent; financial expert)
- Andreas Fibig (re-elected, member since 2018, independent)
- Sylvie Grégoire (re-elected, member since 2015; independent)
- Stig Strøbæk (re-elected, member since 2013, employee representative; not independent)

Under Danish law, four members qualify as independent as defined in the Danish Corporate Governance Recommendations, includ-
ing the chair, and one member, who is an employee representa-
tive, qualifies as non-independent. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Audit Committee adheres to the Danish Corporate Governance Recommendations. In addition, two members, including the chair, have competences in accounting and auditing and the members of the Audit Committee collectively have competences relevant to the healthcare industry as required by the Danish Act on Approved Auditors and Audit Firms.

Pursuant to the US Securities Exchange Act four members qualify as independent while one member, the employee representa-
tive, relies on an exemption to the independence requirements. In addition, two members, including the chair, have been designated as financial experts as defined by the US Securities and Exchange Commission (SEC).

In 2019, the Audit Committee conducted four meetings. All Audit Committee members attended all committee meetings within the member’s term in 2019, except one member who was excused from two meetings within the member’s term in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview.

Audit Committee Report for 2019
According to SEC reporting requirements for listed companies the Audit Committee shall report on their activities.

The Audit Committee works according to an Annual Work Plan with fixed agenda items following key events of the annual financial reporting cycle. In addition, The Audit Committee request topics to be discussed on their meetings from time to time.

For the financial reporting year 2019 the Audit Committee held four meetings and discussed the following matters:
Audit Committee matters and governance

- Conducted a self-evaluation including a review of the Audit Committee Charter and assessment of independence, financial expertise and other legal requirements of each member of the Audit Committee.
- Conducted private meetings with selected members of Executive Management, General Counsel, Head of Group Internal Audit and with the external auditors.

Review of internal and external audit matters

- Evaluated the performance and the independence of the external auditor.
- Recommended the re-election of the current external auditor to the Board of Directors and annual general meeting in 2020.
- Executed an audit tender process and recommended a new external auditor to the Board of Directors. A new external auditor is to be elected at the annual general meeting in 2021.
- Reviewed the performance, independence, effectiveness and organisation of the internal audit function including a review of the charter for Group Internal Audit.
- The Head of Group Internal Audit and the external auditor presented the audit planning and audit resources. In addition, they presented the annual conclusion and results of audit activities conducted each quarter for review including the conclusion of the audit of internal controls over financial reporting.
- Assessed the performance of targets and the remuneration for the head of Group Internal Audit.
- Furthermore, the external auditor presented its annual long form report, and the annual Audit Committee Report required by the PCAOB.
- The Audit Committee reviewed and approved the pre-approval procedure for audit, non-audit and tax services to external auditors, reviewed the given pre-approvals for the current year and pre-approved the level for the next financial year (including engagement letter). Further the Audit Committee reviewed the procedure for hiring employees from external auditors.

Financial, social and environmental reporting

- Discussed with the CFO, Head of Finance and Compliance, the General Counsel, Head of Group Internal Audit and the external auditors:
  - material and relevant new accounting pronouncement, implementation of such, review of key accounting policies and the accounting for certain transactions and activities,
  - accounting for significant legal and tax issues,
  - critical accounting estimates,
  - transactions with related parties, and
  - the scope of internal controls over financial reporting in relation to the requirements in the Sarbanes Oxley Act and Danish legislation.

The Audit Committee performed a review of:

- the global finance organisation,
- the financial statement releases for the full year and interim financial reports,
- the Annual Report including the statements of financial, social and environmental performance, and the Form-20 F,
- the bi-annual risk management reporting,
- the risk reporting process,
- the company’s financial counterpart exposure in the company’s treasury policy, and approved an update hereto, and
- the appropriateness of the insurance coverage regarding property, business interruption and product liability.
- The Audit Committee performed a fraud risk assessment in Novo Nordisk.

Other matters

- Reviewed the Compliance reporting from the Business Ethics Compliance officer, and the US Compliance officer.
- Reviewed issues reported via Compliance Hotline and the Audit Committee agreed on the performed investigations, conclusions and sanctions reached.
- Reviewed the Information Security activities and focus areas.
- On behalf of the Board of Directors, reviewed the Diabetes API capacity investment in the US.

Remuneration Committee

Roles and responsibilities, composition, independence and attendance

The Remuneration Committee has four members elected by the Board of Directors from among its members. One member is designated as chair and one member is an employee representative. The Remuneration Committee assists the Board with oversight of a) the remuneration policy for the members of the Board of Directors and Executive Management, including guidelines on incentive pay to Executive Management referred to as “The principles for remuneration of board members and executives in Novo Nordisk A/S ("Remuneration Principles")”, b) the remuneration of the members of the Board of Directors and its committees, c) the remuneration of the members of Executive Management, and d) other tasks on an ad hoc basis as specifically decided by the Board.

The Board of Directors has in March 2019 elected the following members to the Remuneration Committee:

- Jeppe Christiansen (re-elected, member since 2015 and chair since 2017; not independent)
- Brian Daniels (re-elected, member since 2018, independent)
- Liz Hewitt (re-elected, member since 2018; independent)
- Anne Marie Kverneland (re-elected, member since 2017; employee representative; not independent)

The Remuneration Committee consists of two non-independent members, including the chair, and two independent members pursuant to the Danish Corporate Governance Recommendations. One member is an employee representative. According to the Danish Corporate Governance Recommendations and Danish legislation a majority of the members of a board committee should qualify as independent. Hence, the composition of the Remuneration Committee does not conform to the Danish Corporate Governance Recommendations. This is due to the fact that the Board of Directors finds that the composition of the Remuneration Committee allows for a member from the Chairmanship who is a representative of the main shareholder and an employee representative, who both qualify as
The Remuneration Committee conducted five meetings in 2019. All Remuneration Committee members attended all committee meetings within the member’s term in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview.

Remuneration Committee Report for 2019
The Remuneration Committee works according to an Annual Work Plan with fixed agenda items. In addition, the Remuneration Committee meets when developments require additional meetings.

In 2019 the Remuneration Committee met five times and dealt with the following matters:

- Remuneration of the members of the Board of Directors and its committees
  - Reviewed Danish, Nordic and European Benchmark Data on Board and Board Committee remuneration and recommended to the Board the remuneration levels, multiples and allowances for 2020 to be approved by the Annual General Meeting.
  - Reviewed Group Internal Audit’s report on Board remuneration.

- Remuneration of executives – general review of executive remuneration
  - Undertook a general review of executive remuneration, reviewed feedback from investors on executive remuneration and recommended to the Board changes to the executive remuneration such as base salary, pension, short-term cash-based incentive program, long-term share-based incentive program, shareholdings requirements etc.
  - Recommended to the Board changes in remuneration in 2019 and as well as the general remuneration level for 2020.
  - Reviewed the short-term cash-based incentive programme for the Executive Management and recommended to the Board the structure for 2020.
  - Reviewed the long-term share-based incentive programme for the Executive Management and recommended to the Board the structure for 2020.
  - Reviewed the shareholding requirements for executives as well as the executives’ adherence to the shareholding requirements.
  - Reviewed Group Internal Audit’s report on executive remuneration.

- Remuneration Policy for the members of the Board of Directors and Executive Management
  - Reviewed and recommended to the Board changes to a new Remuneration Policy in light of the general review of the executive remuneration and the requirements in the Shareholders Rights Directive to be approved by the Annual General Meeting.

- Reporting on Remuneration
  - Undertook the development of a new separate Remuneration Report to further enhance transparency in remuneration reporting and to align with future requirements in the Shareholder Rights Directive for comparison purposes.

Remuneration Committee matters and governance
- Conducted a self-assessment including a review of the Remuneration Committee Charter.
- Conducted private meetings without the assigned executive being present.
- Endorsed the report on the Remuneration Committee’s activities.

Special focus areas
- Remuneration of executives – general review of executive remuneration, incl. base salary, pension, short-term cash-based incentive program, long-term share-based incentive program, shareholding requirement etc.
- Remuneration Policy – development of new Remuneration Policy to be approved by the Annual General Meeting.
- Remuneration Report – development of new separate Remuneration Report to be presented to the Annual General Meeting.

Research & Development Committee

Roles and responsibilities, composition, independence and attendance
The Research & Development Committee has four members elected by the Board of Directors from among its members. One member is designated as chair and one member is an employee representative.

The Research & Development Committee assists the Board of Directors with the oversight of: a) the Research & Development strategy, b) the pipeline, c) the R&D organisation, and d) other tasks on an ad hoc basis, as specifically decided by the Board.

The Board of Directors has in March 2019 elected the following members to the Research & Development Committee:

- Martin Mackay (re-elected, chair and member since 2018; independent)
- Brian Daniels (re-elected, member since the establishment in 2017; independent)
- Sylvie Gregoire (re-elected, member since the establishment in 2017; independent)
- Thomas Rantzau (re-elected, member since 2018; employee representative; not independent)

The Research & Development Committee consists of three members who are independent, including the chair, as defined in the Danish Corporate Governance Recommendations and one member, the employee representative, who is non-independent. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Research & Development Committee adheres to the Danish Corporate Governance Recommendations.
The Research & Development Committee conducted six meetings in 2019. All Research & Development Committee members attended all committee meetings within the member’s term in 2019. Please refer to the Annual Report on p. 39 for a detailed attendance overview.

**Research & Development Committee Report for 2019**

The R&D Committee works according to an Annual Work Plan with fixed agenda items. In addition, the R&D Committee meets when developments require additional meetings. The R&D Committee has in 2019 met six times and dealt with the following matters:

**R&D pipeline update**

- Regularly reviewed progress of the development project pipeline, including initiation and results of clinical trials, submission of application for marketing authorisations, and receipt of marketing authorisations for key development projects.
- Reviewed progress of the research project pipeline, including key challenges and initiatives within early innovation and new therapeutic areas.

**Progress within external innovation sourcing**

- Discussed the increased need for external innovation sourcing.
- Regularly reviewed potential as well as completed external innovation sourcing opportunities, including potential acquisitions and licensing opportunities.

**Implementation of the R&D Strategy**

- Reviewed the overall investment strategy.
- Reviewed the research strategy within NASH.
- Reviewed the long-term succession planning.

**R&D Committee matters and governance**

- Reviewed and suggested changes to the R&D Committee charter.
- Conducted private meetings without the assigned executive being present.
- Reviewed and endorsed a report on the R&D Committee’s activities.

**Special focus areas**

- GLP-1 (subcutaneous and oral): Reviewed results of clinical trials conducted and discussed potential additional research and development activities to further explore opportunities within subcutaneous and oral GLP-1 as well as competitor initiatives.
- NASH: Discussed the potential opportunities to address unmet needs.
- External innovation sourcing: Reviewed potential external research collaborations as well as acquisitions.

**Executive Management**

Executive Management is responsible for the overall day-to-day management, the organisation of the company, allocation of resources, determination and implementation of strategies and policies, direction setting, and ensuring timely reporting and provision of information to the Board of Directors and Novo Nordisk’s stakeholders. Executive Management meets at least once a month, and often more frequently. The Board of Directors appoints members of Executive Management and determines their remuneration. The Chairmanship reviews the performance of the executives. To ensure the organisational implementation of the strategy, Executive Management has established a Management Board consisting of the chief executive officer, executive vice presidents and senior vice presidents.

As of 31 December 2019, Executive Management consisted of nine members including the chief executive officer. As of April 2019, Jesper Brandgaard retired from Novo Nordisk and Ludovic Helfgott was appointed executive vice president, head of Biopharm. As of August 2019, Monique Carter was appointed executive vice president, head of People & Organisation and Lars Green resigned from Novo Nordisk.

As of 5 February 2020, Executive Management consists of the following members:

- Lars Frueergaard Jørgensen (president & chief executive officer (CEO))
- Monique Carter (executive vice president and head of People & Organisation)
- Maziar Mike Doustdar (executive vice president and head of International Operations)
- Ludovic Helfgott (executive vice president and head of Biopharm)
- Karsten Munk Knudsen (executive vice president and chief financial officer (CFO))
- Doug Langa (executive vice president and head of North America Operations)
- Camilla Sylvest (executive vice president and head of Commercial Strategy & Corporate Affairs)
- Mads Krogsgaard Thomsen (executive vice president and chief science officer (CSO))
- Henrik Wulff (executive vice president and head of Product Supply)

The three executives who are based outside of Denmark and who have responsibility for Biopharm, International Operations and North America Operations respectively are not registered as executives with the Danish Business Authority.

**Risk management**

Novo Nordisk’s risk management process is governed by Executive Management and designed to ensure that key business risks are effectively identified, assessed and mitigated so that they do not affect the company’s ability to achieve its business objectives. The risk management system covers Novo Nordisk in terms of geography, activities and functional areas.

All business activity has inherent risk. Our approach to risk management is to proactively manage risk to ensure continued growth.
of our business and to protect our people, assets and reputation. This means that we:

- utilise an effective and integrated risk management system while maintaining business flexibility,
- identify and assess material risks associated with our business, and
- monitor, manage and mitigate risks.

Our risk willingness depends upon the specific category of risk and examples of such categories are:

- Delays or failure of products in pipeline
- Supply distributions
- Competition and market development
- Compromises to product quality and patient safety
- Information technology security breaches
- Currency impact and tax disputes
- Breach of legislation or ethical standards
- Loss of intellectual property rights

Please refer to the Annual Report 2019 pp. 29-31 for a more detailed description of the above categories and Novo Nordisk’s key risks.

The enterprise risk management system
In Novo Nordisk, management teams in all organisational areas are responsible for continuous identification, assessment, and mitigation of risks. All areas have procedures and infrastructure to ensure successful management and reporting of risks, with dedicated local risk coordinators facilitating the process and providing advice and training. This setup allows us to respond timely to risks.

Biannually, management teams are required to report to the Insurance & Enterprise Risk department their most significant risks, along with assessments and an overview of implemented mitigations and next milestones. All risk assessments take into account the likelihood of an event and its potential impact on the business. Impact is quantified and assessed in terms of potential financial loss or reputational damage. Risks are assessed both as gross risk and net risk.

Insurance & Enterprise Risk then challenges management on the reported risk information (including assessments, implemented mitigations and next milestones), and consolidates on a biannual basis reported risks into a corporate profile containing the company’s key risks. The final risk profile is reviewed by Executive Management, the Audit Committee and the Board of Directors.

Internal control

Overall control environment
The Board of Directors and Executive Management set out general requirements for business processes and internal controls. A number of policies are defined by Executive Management and approved by the Board of Directors, including:

- Finance Policy
- Legal Policy
- Risk Management Policy
- Treasury Policy
- Information Technology Policy
- Business Ethics Policy

A description of Novo Nordisk’s overall policies, positions and values can be found in the Annual Report, ‘Leading a sustainable business’ on pp. 8-10.

Responsibility for maintaining sufficient and effective internal controls and risk management system in relation to the financial reporting is anchored with Executive Management. Executive Management ensures design and implementation of controls considered necessary to mitigate risks identified in relation to the financial reporting process.

The Audit Committee appointed by the Board of Directors monitors on an ongoing basis the assessment of risk and the design and operating effectiveness of the implemented internal controls in connection with the financial reporting process.

The internal audit function, Group Internal Audit, is reporting to the Audit Committee. The internal audit function provides independent and objective assurance primarily within internal control and governance.

Risk assessment
The Audit Committee and Executive Management perform assessments of the risk exposure of Novo Nordisk, including the impact on the financial reporting and the financial reporting process. Quarterly, the Audit Committee have discussions with the chief financial officer, head of finance, head of business assurance, head of group internal audit, the external auditor and the general counsel regarding:

- material and relevant new accounting pronouncement, implementation of such, review of key accounting policies and the accounting for certain transactions and activities, and
- accounting for material legal and tax issues - significant accounting estimates, and the scope and effectiveness of internal controls over financial reporting including Sarbanes-Oxley requirements.

The identified key risks in relation to the financial reporting are described in the statutory Annual Report for 2019 in the sections ‘Novo Nordisk’s key risks’ on pp. 29-31 and Note 1.1 ‘Principal accounting policies and key accounting estimates’.

Control activities
The internal control system which has been based on the COSO framework includes clearly defined organisational roles and responsibilities, reporting requirements and authorities. Novo Nordisk is in compliance with the Sarbanes–Oxley Act section 404, which requires detailed documentation of the design and operation of financial reporting processes. Novo Nordisk must ensure that there are no material weaknesses in the internal
controls that could lead to a material misstatement in its financial reporting.

The company’s conclusion and the auditor’s evaluation of these processes are included in the company’s Form 20-F filing to the US Securities and Exchange Commission (SEC).

**IT systems**

Novo Nordisk operates with a common global IT system that ensures uniformity and transparency in data used for the financial reporting and controlling. Information and communication systems to ensure accounting and internal control compliance are established including accounting manual, internal control requirements, budgeting manual and other relevant guidelines. This information is available for all employees on the Intranet.

**Monitoring**

Each month the group’s companies report financial data and comments on financial and commercial developments to the central accounting and controlling function. This information is used to prepare consolidated financial statements and reports for the group’s Executive Management. Financial reporting, including reporting from subsidiaries, are controlled on an ongoing basis. In connection with the preparation of the Annual Report, additional analysis and control activities are performed to ensure proper presentation in the Annual Report.

Test of internal controls over financial reporting by Group Internal Audit and external auditors and management’s self-assessment of the controls are conducted as a part of the compliance with the Sarbanes–Oxley Act section 404. The result hereof is reported to the Audit Committee on a quarterly basis.
Appendix 1

Deviations from Nasdaq Copenhagen Corporate Governance Recommendations

As a company organised under Danish law and with a primary listing on Nasdaq Copenhagen, Novo Nordisk is in compliance with Danish securities law and it is Novo Nordisk’s intent to be guided by the Danish Corporate Governance Recommendations announced by Nasdaq Copenhagen (prepared by the Danish Committee on Corporate Governance). Nasdaq Copenhagen has required Danish companies to report on a “comply-or-explain” basis their compliance with these recommendations. Novo Nordisk is in compliance with all but five of the Danish Corporate Governance Recommendations.

The Danish Corporate Governance Recommendations

<table>
<thead>
<tr>
<th>Danish Corporate Governance Recommendations</th>
<th>Novo Nordisk’s approach</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3.3.2</strong></td>
<td>The Committee recommends that the management commentary, in addition to the provisions laid down by legislation, includes the following information about the members of the board of directors:</td>
</tr>
<tr>
<td>• the position of the relevant person;</td>
<td>The information mentioned in bullets no. 1 to no. 8 are disclosed in the management commentary.</td>
</tr>
<tr>
<td>• the age and gender of the person in question;</td>
<td>Novo Nordisk has prepared a separate Remuneration Report that describes the remuneration awarded or due during 2019 to the members of the Board and the Executive Management of Novo Nordisk A/S as registered with the Danish Business Authority. The Remuneration Report is available at: <a href="https://www.novonordisk.com/about-novo-nordisk/corporate-governance/remuneration.html">https://www.novonordisk.com/about-novo-nordisk/corporate-governance/remuneration.html</a>.</td>
</tr>
<tr>
<td>• the person’s competencies and qualifications that are relevant to the company;</td>
<td>Thus information on number of shares, options, warrants and similar owned by the Board member in the company, and other group companies, as well as changes to the Board member’s portfolio of the mentioned securities which have occurred during the financial year are now disclosed in the Remuneration Report.</td>
</tr>
<tr>
<td>• whether the member is considered independent;</td>
<td>Consequently, the information mentioned in the last bullet, no. 9, are disclosed in the Remuneration Report and not in the management commentary.</td>
</tr>
<tr>
<td>• the member’s date of appointment to the board of directors;</td>
<td></td>
</tr>
<tr>
<td>• expiry of the current election term;</td>
<td></td>
</tr>
<tr>
<td>• the member’s participation in the meetings of the board of directors and committee meetings;</td>
<td></td>
</tr>
<tr>
<td>• other management functions, including memberships in executive boards, boards of directors, and supervisory boards, including board committees in Danish and foreign enterprises and demanding organisational tasks; and</td>
<td></td>
</tr>
<tr>
<td>• the number of shares, options, warrants and similar owned by the member in the company, and other group companies, as well as changes to the member’s portfolio of the mentioned securities which have occurred during the financial year.</td>
<td></td>
</tr>
</tbody>
</table>

**3.4.2** The Committee recommends that a majority of the members of a board committee be independent.

The Board of Directors of Novo Nordisk wishes to allow for both an employee elected Board member as well as a representative of the main shareholder to be on a committee while keeping the number of committee members small. Consequently the composition of the Nomination Committee and of the Remuneration Committee does not adhere to the recommendation.
3.4.6 The Committee recommends that the board of directors establish a nomination committee, which is at least, responsible for the following preparatory tasks:

- describing the qualifications required by the board of directors and the executive board and for a given position, indicating the time expected to be spent carrying out a specific position, as well as assessing the competencies, knowledge and experience found in the two governing bodies,
- annually assessing the structure, size, composition and results of the board of directors and the executive board and recommend any changes to the board of directors,
- annually assessing the competencies, knowledge, experience and succession of the individual members of management, and report to the board of directors in this respect,
- recommending candidates for the board of directors and the executive board, and
- proposing an action plan to the board of directors on the future composition of the board of directors, including proposals for specific changes.

The Board has established a Nomination Committee. The Board has approved a Charter for the Nomination Committee setting out its responsibilities and powers.

The primary focus for the Nomination Committee remains with defining the qualifications and assess the composition and skills of the Board of Directors while at the same time ensuring the continuity and alignment in the succession planning of the Board of Directors, while the Chairmanship is responsible for succession management and recommending candidates for the Executive Management.

3.4.7 The Committee recommends that the board of directors establish a remuneration committee, which is at least, responsible for the following preparatory tasks:

- recommending the remuneration policy (including the “General Guidelines for incentive-based Remuneration”) to the board of directors and the executive board for approval by the board of directors prior to approval by the general meeting,
- making proposals to the board of directors on remuneration for members of the board of directors and the executive board, as well as ensuring that the remuneration is in compliance with the company’s remuneration policy and the assessment of the performance of the persons concerned. The committee should have information on the total remuneration that members of the board of directors and the executive board receive from other companies in the group,
- recommending a remuneration policy applicable for the company in general, and
- assisting with the preparation of the annual remuneration report.

The Board has established a Remuneration Committee and it has approved a Charter for the Remuneration Committee setting out its responsibilities and powers.

In accordance with its Charter the Remuneration Committee carries out the tasks regarding remuneration to the Board of Directors and Executive Management, while the responsibility of the remuneration policy applicable for the company in general lies with Executive Management.

The Remuneration Committee assists with the preparation of the Remuneration Report.

4.1.5 The Committee recommends that the total value of the remuneration relating to the notice period, including severance pay, do not exceed two years of remuneration, including all components of the remuneration.

Except for executive employment contract entered into before 2008, the total value of the remuneration relating to the notice period, and of the severance pay, for each individual executive does not exceed two years of remuneration, including all components of the remuneration.

The executive employment contract entered into before 2008 allow for severance payments of more than 24 months’ fixed base salary plus pension contribution and thus the total value of the remuneration relating to the notice period, and of the severance pay, exceeds two years of remuneration, including all components of the remuneration.
Appendix 2

Summary of the significant ways in which Novo Nordisk’s corporate governance practices differ from the NYSE Corporate Governance Listing Standards

Novo Nordisk is a foreign listed private issuer whose ADRs are listed on the New York Stock Exchange (the ‘NYSE’). As such, Novo Nordisk is required to comply with US securities laws, including the Sarbanes-Oxley Act and the NYSE Corporate Governance Standards except that, as permitted under these standards, Novo Nordisk continues to apply Danish corporate governance practices in certain areas.

Below a summary is provided of the significant ways in which Novo Nordisk’s corporate governance practices differ from the corporate governance standards of the NYSE applicable to domestic US-listed companies.

NYSE Listed Company Manual – Section 303A

<table>
<thead>
<tr>
<th>Corporate Governance standard</th>
<th>Novo Nordisk corporate governance practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rule 2.(a)(i)</td>
<td>No director qualifies as ‘independent’ unless the board of directors affirmatively determines that the director has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). Under the Danish Corporate Governance Recommendations, at least half of the shareholder-elected members of the board of directors, excluding any members that have been elected by employees of the company, must be independent. Employees are entitled to be represented by half of the total number of board members elected by the shareholders. The Board of Directors has determined whether board members qualify as independent under the Danish Corporate Governance Recommendations. The Board of Directors has also determined whether the board members, who are members of the Audit Committee, qualify as independent under Rule 10A-3 under the Securities Exchange Act. Such determination is disclosed in the statutory Annual Report. Further, the statutory Annual Report provides detailed and individual information regarding the board members, but it does not explicitly identify which board members the Board of Directors consider independent under NYSE’s Corporate Governance Listing Standards.</td>
</tr>
</tbody>
</table>
| Rule 2.(a)(ii)               | In addition, in affirmatively determining the independence of any director who will serve on the compensation committee of the listed company’s board of directors, the board of directors must consider all factors specifically relevant to determining whether a director has a relationship to the listed company which is material to that director’s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to:  
(A) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the listed company to such director; and  
(B) whether such director is affiliated with the listed company, a subsidiary of the listed company or an affiliate of a subsidiary of the listed company. It is not a requirement to have a compensation committee if a company is ‘controlled’, which the New York Stock Exchange defines as having more than 50% of the voting power for the election of directors held by an individual, a group or another company. Novo Nordisk is such a controlled company and is therefore exempt from the requirement to establish a separate compensation committee in the same manner as US companies are. The Board has established a Remuneration Committee and the Remuneration Committee consists of two non-independent members, including the chair, and two independent members pursuant to the Danish Corporate Governance Recommendations. One member is an employee representative. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Remuneration Committee does not conform to the Danish Corporate Governance Recommendations. |
<table>
<thead>
<tr>
<th><strong>Danish Corporate Governance Recommendations</strong></th>
<th><strong>Novo Nordisk's approach</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>This is due to the fact that the Board of Directors finds that the composition of the Remuneration Committee allows for a member from the Chairmanship who is a representative of the main shareholder and an employee representative, who both qualify as non-independent Board members, being on the Remuneration Committee while maintaining an operational structure of the Remuneration Committee with relative few members.</td>
<td></td>
</tr>
<tr>
<td>The Board of Directors considers all factors relevant to determine whether the members of the Remuneration Committee have a relationship to Novo Nordisk which is material to the director’s ability to be independent from management when performing its duties.</td>
<td></td>
</tr>
<tr>
<td>Rule 2.(b)(i)</td>
<td>In addition, a director is not independent if the director is, or has been within the last three years, an employee of the listed company, or an immediate family member is, or has been within the last three years, an executive officer, of the listed company.</td>
</tr>
<tr>
<td>Rule 2.(b)(ii)</td>
<td>A director is not independent if the director has received, or has an immediate family member who has received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from the listed company, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such compensation is not contingent in any way on continued service).</td>
</tr>
<tr>
<td>Rule 303A.02 defines 'listed company', for purposes of the independence standards, to include 'any parent or subsidiary in a consolidated group with the listed company or such other company as is relevant to any determination under the independence standards set forth in this Section 303A.02(b)'.</td>
<td></td>
</tr>
<tr>
<td>Definition of 'listed company' is identical to what is stated under Rule 2.(b)(i).</td>
<td></td>
</tr>
<tr>
<td>Four employees have in accordance with the requirements in the Danish Companies Act been elected as board members by the Danish employees of the company.</td>
<td></td>
</tr>
<tr>
<td>One director serves as chief executive officer of the main shareholder, Novo Holdings A/S.</td>
<td></td>
</tr>
<tr>
<td>No other board member or the board member’s immediate family members have within the last three years been an employee or executive of Novo Nordisk or any parent or subsidiary in a consolidated group with Novo Nordisk.</td>
<td></td>
</tr>
<tr>
<td>No other board members or immediate family member receives or has received such fees from Novo Nordisk.</td>
<td></td>
</tr>
<tr>
<td>Rule 4.(a)</td>
<td>Listed companies must have a nominating/corporate governance committee composed entirely of independent directors.</td>
</tr>
<tr>
<td>The requirement does not apply if a company is ‘controlled’, which the New York Stock Exchange defines as having more than 50% of the voting power for the election of directors held by an individual, a group or another company. Novo Nordisk is such a controlled company and is therefore exempt from this requirement in the same manner as US companies are.</td>
<td></td>
</tr>
</tbody>
</table>
| The Board has established a Nomination Committee and the Nomination Committee consists of two members who are independent, including the chair, as defined in the Danish Corporate Governance Recommendations and two members who are non-independent. One member is an employee representative. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Nomination Committee does not conform to the
<table>
<thead>
<tr>
<th>Danish Corporate Governance Recommendations</th>
<th>Novo Nordisk’s approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwegian Corporate Governance Recommendations. This is due to the fact that the Board of Directors finds that the composition of the Nomination Committee allows for a representative of the main shareholder, who qualifies as a non-independent Board member, as well as an employee representative, who also qualifies as a non-independent Board member, being on the Nomination Committee while maintaining an operational structure of the Nomination Committee with relative few members.</td>
<td></td>
</tr>
<tr>
<td>The Board of Directors considers all factors relevant to determine whether the members of the Nomination Committee have a relationship to Novo Nordisk which is material to the director's ability to be independent from management when performing its duties.</td>
<td></td>
</tr>
<tr>
<td>The Nomination Committee is responsible for the oversight of the company’s corporate governance practices.</td>
<td></td>
</tr>
</tbody>
</table>

**Rule 5.(a)**

Listed companies must have a compensation committee composed entirely of independent directors. Compensation committee members must satisfy the additional independence requirements specific to compensation committee membership set forth in section 303A.02(a)(ii).

The requirement does not apply if a company is 'controlled', which the New York Stock Exchange defines as having more than 50% of the voting power for the election of directors held by an individual, a group or another company. Novo Nordisk is such a controlled company and is therefore exempt from this requirement in the same manner as US companies are.

The Board has established a Remuneration Committee and the Remuneration Committee consists of two non-independent members, including the chair, and two independent members pursuant to the Danish Corporate Governance Recommendations. One member is an employee representative. According to the Danish Corporate Governance Recommendations a majority of the members of a board committee should qualify as independent. Hence, the composition of the Remuneration Committee does not conform to the Danish Corporate Governance Recommendations. This is due to the fact that the Board of Directors finds that the composition of the Remuneration Committee allows for a member from the Chairmanship who is a representative of the main shareholder and an employee representative, who both qualify as non-independent Board members, being on the Remuneration Committee while maintaining an operational structure of the Remuneration Committee with relative few members.

The Board of Directors considers all factors relevant to determine whether the members of the Remuneration Committee have a relationship to Novo Nordisk which is material to the director's ability to be independent from management when performing its duties.

Furthermore, the Chairmanship annually evaluates the performance and target setting for Executive Management.

**Rule 7.(a)**

The audit committee must have a minimum of three members. All audit committee members must satisfy the requirements for independence set out in Section 303A.02 and, in the absence of an applicable exemption, Rule 10A-3(b)(1).

The Audit Committee has five members.

Four Audit Committee members satisfy the independence requirements of Rule 10A – 3(b)(1) of the Securities Exchange Act and section 303A.02 of the NYSE Listed Company Manual.

One Audit Committee member is an employee representative relying on the exemption from the independence requirements in Rule 10A-3(b)(1) provided for by paragraph (b)(1)(ii)(C).

Novo Nordisk does not believe the reliance on such exemption will materially affect the ability of the Audit Committee to act independently.
| Rule 7.(b)(i) | The audit committee must have a written charter that addresses the committee’s purpose – which, at minimum, must be to: |
| Rule 7.(b)(i)(A) | assist board oversight of (1) the integrity of the listed company’s financial statements, (2) the listed company’s compliance with legal and regulatory requirements, (3) the independent auditor’s qualifications and independence, and (4) the performance of the listed company’s internal audit function and independent auditors (if the listed company does not yet have an internal audit function because it is availing itself of a transition period pursuant to Section 303A.00, the charter must provide that the committee will assist board oversight of the design and implementation of the internal audit function). |
| Novo Nordisk’s approach | The Audit Committee Charter addresses the Committee’s purpose. As stated in the Charter, the Audit Committee is, amongst other things, responsible for oversight of and reporting to the Board of Directors on the elements described in the recommendation. However, with respect to legal and regulatory requirements, the Audit Committee’s oversight responsibility only includes oversight of compliance with legal and regulatory requirements relating to business ethics compliance. The Audit Committee Charter is available on novonordisk.com. |
| Rule 8 | Shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions thereto, with limited exemptions explained below. |
| [Text abbreviated] | The Remuneration Principles are approved by the Annual General Meeting. The Remuneration Principles describe the framework for incentive programs for the Board and Executive Management. All incentive programs offered to the Board of Directors and/or Executive Management shall comply with this framework. However, under Danish law, the practice of voting on equity-compensation plans is not contemplated and accordingly, equity compensation plans are only subject to shareholder approval if it results in the issuance of new shares (and not if treasury shares are used). |
| Rule 10 | Listed companies must adopt and disclose a code of business conduct and ethics for directors, officers and employees, and promptly disclose any waivers of the code for directors or executive officers. |
| According to NYSE commentary, a code of business conduct and ethics shall include: | Novo Nordisk has a framework of rules and guidelines, including but not limited to the Novo Nordisk Way, the Business Ethics Code of Conduct and the supporting Business Ethics Compliance Framework, which describe corporate values and required mindset and action on business conduct and ethics. |
| • Conflicts of interest. | While certain topics mentioned in the NYSE Listed Company Manual are addressed in this framework of rules and guidelines there may be topics, which are not covered. |
| • Corporate opportunities. | The Business Ethics Code of Conduct is available on Novo Nordisk’s website. |
| • Confidentiality. | |
| • Fair dealing. | |
| • Protection and proper use of company assets. | |
| • Compliance with laws, rules and regulations (including insider-trading laws). | |
| • Encouraging the reporting of any illegal or unethical behaviour. | |
| Rule 12.(a) | Each listed company CEO must certify to the NYSE each year that he or she is not aware of any violation by the listed company of NYSE corporate governance listing standards, qualifying the certification to the extent necessary. |
| Listed companies that are foreign private issuers are permitted to follow home country practice in lieu of the provisions of this section. Novo Nordisk has opted to follow Danish law and regulations, which do not contemplate such certifications. However, Novo Nordisk will notify the NYSE promptly in writing if it becomes aware of any non-compliance with applicable NYSE corporate governance rules. |